A Ram Hong

Dr. A Ram Hong

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2021 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
JYJee Hee Yoon
Jee Hee Yoon
AHA Ram Hong
A Ram Hong
HKHee Kyung Kim
Hee Kyung Kim
HKHo-Cheol Kang
Ho-Cheol Kang
Background: Thyroid immune-related adverse events (IRAEs) have been reported in patients treated with programmed cell death protein-1 (PD-1) and programmed cell death protein-ligand 1 (PD-L1) inhibitors. We investigated the incidence and clinical course of PD-1/PD-L1 inhibitor-induced thyroid IRAEs, and identified predictable clinical risk factors of thyroid IRAEs, in particular, overt hypothyroidism (OH).Methods: We retrospectively reviewed the medical records of 325 cancer patients receiving PD-1/PD-L1 inhibitor in a tertiary referral center.Results: A total of 50.5% (164/325) of patients experienced at least one abnormal thyroid function following PD-1/PD-L1 inhibitor. Eighty-four patients (51.2%) of them recovered to normal thyroid function during follow-up. In overall population, 25 patients (7.7%) required thyroid hormone replacement therapy due to PD-1/PD-L1 inhibitor-induced OH. Patients who progressed to OH showed significantly higher baseline thyroid stimulating hormone level and longer duration of PD-1/PD-L1 inhibitor therapy than those without thyroid dysfunction or OH (both P<0.001). Median time interval to the development of OH was 3 months after the therapy. OH was significantly associated with positive anti-thyroid peroxidase antibody at baseline and anti-thyroglobulin antibody during the therapy than those without thyroid dysfunction or OH (P=0.015 and P=0.005, respectively). We observed no patients with OH who were able to stop levothyroxine replacement after the cessation of PD-1/PD-L1 inhibitor therapy.Conclusion: PD-1/PD-L1 inhibitor-induced thyroid dysfunctions are considerably reversible; however, OH is irreversible requiring levothyroxine replacement even after stopping the therapy. Positive thyroid autoantibodies may predict the progression to OH.

1 October 2020 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
JYJee Hee Yoon
Jee Hee Yoon
AHA Ram Hong
A Ram Hong
WCWonsuk Choi
Wonsuk Choi
JPJi Yong Park
Ji Yong Park
HKHee Kyung Kim
Hee Kyung Kim
HKHo-Cheol Kang
Ho-Cheol Kang

30 June 2021 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
HPHyun Woo Park
Hyun Woo Park
HJHyojung Jung
Hyojung Jung
KBKyoung Yeon Back
Kyoung Yeon Back
HCHyeon Ju Choi
Hyeon Ju Choi
KRKwang Sun Ryu
Kwang Sun Ryu
YHYul Hwangbo
Yul Hwangbo

1 January 2019 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
AHA Ram Hong
A Ram Hong
BKBo Kyung Koo
Bo Kyung Koo
SKSang Wan Kim
Sang Wan Kim
KYKa Hee Yi
Ka Hee Yi
MMMin Kyong Moon
Min Kyong Moon
Hong AR, et al. Diabetes Metab J. 2019 Jan;43:e12. https://doi.org/10.4093/dmj.2018.0134

30 April 2023 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
AHA Ram Hong
A Ram Hong
HKHo-Cheol Kang
Ho-Cheol Kang
Thyroid hormones play an important physiological role in maintaining adult bone structure and strength. Consequently, thyroid dysfunction is related to skeletal outcomes. Overt hyperthyroidism is an established cause of high bone turnover with accelerated bone loss, leading to osteoporosis and increased fracture risk. Hyperthyroidism induced by thyroid-stimulating hormone-suppressive therapy in patients with differentiated thyroid cancer is a cause of secondary osteoporosis. In contrast, there is a lack of evidence on the negative impact of hypothyroidism on bone health. Considering the clinical updates on the importance of bone health in thyroid dysfunction, the Task Force from the Clinical Practice Guidelines Development Committee of the Korean Thyroid Association recently developed a position statement on the evaluation and management of bone health of patients with thyroid diseases, particularly focused on endogenous hyperthyroidism and thyroid-stimulating hormone-suppressive therapy-associated hyperthyroidism in patients with differentiated thyroid cancer. Herein, we review the Korean Thyroid Association’s position statement on the evaluation and management of bone health associated with thyroid diseases.

25 January 2016 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
DLDong-Hwa Lee
Dong-Hwa Lee
KJKyong Yeun Jung
Kyong Yeun Jung
AHA Ram Hong
A Ram Hong
JKJung Hee Kim
Jung Hee Kim
Kyoung Min KimKyoung Min Kim
Kyoung Min Kim
SKSang Wan Kim
Sang Wan Kim
The purpose of this study was to determine the relationships among hip geometry, bone mineral density, and the risk of hip fracture in premenopausal women. The participants in this case–control study were 16 premenopausal women with minimal-trauma hip fractures (fracture group) and 80 age-and BMI-adjusted controls. Subjects underwent dual-energy X-ray absorptiometry (DXA) to assess BMD at the proximal femur and to obtain DXA-derived hip geometry measurements. The fracture group had a lower mean femoral neck and total hip BMD than the control group (0.721 ± 0.123 vs. 0.899 ± 0.115, p <0.001 for the femoral neck BMD and 0.724 ± 0.120 vs. 0.923 ± 0.116, p <0.001 for the total hip BMD). In addition, participants in the fracture group had a longer hip axis length (HAL; p = 0.007), narrower neck shaft angle (NSA; p = 0.008), smaller cross sectional area (CSA; p < 0.001) and higher cross sectional moment of inertia (CSMI; p = 0.004) than those in control group. After adjusting for BMD, the fracture group still had a significantly longer mean HAL (p = 0.020) and narrower NSA (p = 0.006) than the control group. BMD is an important predictor of hip fracture in premenopausal women. Furthermore, HAL and NSA are BMD-independent predictors of hip fracture in premenopausal women. Hip geometry may be clinically useful for identification of premenopausal women for whom active fracture prevention should be considered.